BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 25, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tolenix: Additional Phase II data

Additional data from a double-blind, crossover, international Phase II trial in 138 patients showed that twice-daily Tolenix (2 mg tolterodine plus 9 mg pilocarpine) led to a 0.88 reduction in daily urination frequency and a 0.47 reduction in the number of incontinence episodes per day, both co-primary endpoints, vs. placebo (p<0.0001 for both). On...

Read the full 249 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >